Bivalirudin as compared to unfractionated heparin in patients undergoing percutaneous coronary revascularization: A meta-analysis of 22 randomized trials

Thrombosis Research

Volumn 135, Issue 5, 2015, Pages 902-915

  Verdoia, Monica ^a   Schaffer, Alon ^a   Barbieri, Lucia ^a   Suryapranata, Harry ^b   De Luca, Giuseppe ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bivalirudin; Heparin; Meta analysis; Outcome; Percutaneous coronary intervention

Indexed keywords

HEPARIN; HIRULOG; ANTICOAGULANT AGENT; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; ADVERSE EFFECTS; COMPARATIVE STUDY; HEMORRHAGE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOSIS;

ANTICOAGULANTS; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 84928594310     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.03.004     Document Type: Article

References (66)

1. G. De Luca, F. Bellandi, K. Huber, M. Noc, A.S. Petronio, and H.R. Arntz Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis J Thromb Haemost 9 12 2011 2361 2370
2. G. De Luca, and P. Marino Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials Am Heart J 154 2007 1085.e1 1085.e6
3. G. De Luca, E.P. Navarese, E. Cassetti, M. Verdoia, and H. Suryapranata Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy Am J Cardiol 107 2011 198 203
4. G. De Luca, M. Verdoia, and H. Suryapranata Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials Atherosclerosis 222 2012 426 433
5. G. De Luca, J.J. Smit, N. Ernst, H. Suryapranata, J.P. Ottervanger, and J.C. Hoorntje Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction Thromb Haemost 93 2005 820 823
6. G. De Luca, H. Suryapranata, and P. Marino Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of current status Prog Cardiovasc Dis 50 2008 352 382
7. T.E. Warkentin, A. Greinacher, and A. Koster Bivalirudin Thromb Haemost 99 2008 830 839
8. T.D. Gladwell Bivalirudin: a direct thrombin inhibitor Clin Ther 24 1 2002 38 58
9. M. Heras, J.H. Chesebro, and W.S. Penny Effects of thrombin inhibition on development of acute plateletthrombus deposition during angioplasty in pigs Circulation 79 1989 657 665
10. L. Badimon, J. Badimon, and R. Lassila Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation Blood 78 1991 423 434
11. G. Busch, B. Steppich, and D. Sibbing Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention Thromb Haemost 101 2009 340 344
12. Z. Sergie, R. Mehran, and G.W. Stone What is the optimal antithrombotic strategy in primary percutaneous coronary intervention? Curr Opin Cardiol 27 4 2012 361 367
13. S.V. Manoukian, F. Feit, and R. Mehran Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial J Am Coll Cardiol 49 2007 1362 1368
14. S. De Servi, G. Mariani, M. Mariani, and M. D'Urbano How to reduce mortality in ST-elevation myocardial infarction patients treated with primary percutaneous coronary interventions: cut the bleeding Curr Med Res Opin 29 3 2013 189 194
15. G. De Luca, A. Schaffer, J. Wirianta, and H. Suryapranata Comprehensive meta-analysis of radial vs femoral approach in primary angioplasty for STEMI Int J Cardiol 168 2013 2070 2081
16. S. De Servi, G. Mariani, M. Mariani, and M. D'Urbano The bivalirudin paradox: high evidence, low use J Cardiovasc Med (Hagerstown) 14 5 2013 334 341
17. G. De Luca, H. Suryapranata, G.W. Stone, D. Antoniucci, J.E. Tcheng, and F.J. Neumann Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials JAMA 293 2005 1759 1766
18. G. De Luca, E. Navarese, and P. Marino Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials Eur Heart J 30 2009 2705 2713
19. G. Montalescot, D. Antoniucci, A. Kastrati, F.J. Neumann, M. Borentain, and A. Migliorini Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up Eur Heart J 28 2007 443 449
20. A.A. Heestermans, J.W. van Werkum, D. Taubert, T.H. Seesing, N. von Beckerath, and C.M. Hackeng Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction Thromb Res 122 6 2008 776 781
21. R. Shelton, C. Eftychiou, K. Somers, A. Liu, N. Burton-Wood, and M. Anderson Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population EuroIntervention 9 2013 118 122
22. G. De Luca, E. Cassetti, M. Verdoia, and P. Marino Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: A meta-analyis of randomised trials Thromb Haemost 102 3 2009 428 436
23. G.G. Biondi-Zoccai, A. Abbate, P. Agostoni, Q. Parisi, M. Turri, and M. Anselmi Stenting versus surgical bypass grafting for coronary artery disease: systematic overview and meta-analysis of randomized trials Ital Heart J 4 2003 271 280
24. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, and J.P. Ioannidis The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Ann Intern Med 151 2009 W65 W94
25. G.W. Stone, H.D. White, and E.M. Ohman Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial Lancet 369 2007 907 919
26. G. Patti, V. Pasceri, L. D'Antonio, A. D'Ambrosio, M. Macrì, and G. Dicuonzo Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study) Am J Cardiol 110 4 Aug 15 2012 478 484
27. G. Parodi, A. Migliorini, R. Valenti, B. Bellandi, U. Signorini, and G. Moschi Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial) Am J Cardiol 105 8 Apr 15 2010 1053 1059
28. J.A. Bittl, B.R. Chaitman, and F. Feit Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Hirulog Angioplasty Study Am Heart J 142 2001 952 959
29. A.M. Lincoff, N.S. Kleiman, and K. Kottke-Marchant Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during Percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET) Am Heart J 143 2002 847 853
30. P.G. Steg, A. van 't Hof, C.W. Hamm, P. Clemmensen, F. Lapostolle, and P. Coste Bivalirudin Started during Emergency Transport for Primary PCI N Engl J Med 369 23 Dec 5 2013 2207 2217
31. G.W. Stone, B. Witzenbichler, G. Guagliumi, J.Z. Peruga, B.R. Brodie, and D. Dudek Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial Lancet 377 9784 2011 2193 2204
32. S. Shulz, J. Mehilli, and G. Ndrepepa Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial Eur Heart J 31 2010 582 587
33. S. Shulz, A. Kastrati, and M. Ferenc One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial EuroIntervention 9 2013 430 436
34. D. Tavano, G. Visconti, and D. D'Andrea Comparison of Bivalirudin Monotherapy Versus Unfractionated Heparin Plus Tirofiban in Patients With Diabetes Mellitus Undergoing Elective Percutaneous Coronary Intervention Am J Cardiol 104 2009 1222 1228
35. A.M. Lincoff, J.A. Bittl, and N.S. Kleiman REPLACE-1 Investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial) Am J Cardiol 93 2004 1092 1096
36. A.M. Lincoff, J.A. Bittl, and R.A. Harrington REPLACE- 2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during Percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863
37. S. Schulz, G. Richardt, K.L. Laugwitz, R. Mehran, A.H. Gershlick, and T. Morath Comparison of Prasugrel and Bivalirudin vs Clopidogrel and Heparin in Patients With ST-Segment Elevation Myocardial Infarction: Design and Rationaleof the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Trial Clin Cardiol Mar 14 2014 10.1002/clc.22268 [Epub ahead of print]
38. R. Waksman, O. Bertrand, M. Driesman, L. Gruberg, J. Rossi, and S. Mehta Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III) J Interv Cardiol 26 2 2013 107 113
39. A. Shahzad, I. Kemp, C. Mars, K. Wilson, C. Roome, and R. Cooper HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial Lancet 384 9957 Nov 22 2014 1849 1858
40. C. Briguori, G. Visconti, A. Focaccio, M. Donahue, B. Golia, and L. Selvetella Novel Approaches for Preventing or Limiting Events (NAPLES III) Trial: randomised comparison of bivalirudin versus unfractionated heparin in patients at high risk of bleeding undergoing elective coronary stenting throught the femoral approach. rationale and design Cardiovasc Drugs Ther. 28 3 Jun 2014 273 279
41. H. Yaling Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI. Thirty-Day and One-Year Outcomes of the BRIGHT Trial TCT 2014 [ http://www.cardiosource.org/News-Media/Publications/Cardiology-Magazine/2014/09/BRIGHT-Bivalirudin-Monotherapy-vs-Heparin-Monotherapy-vs-Heparin-Plus-Tirofiban-in-AMI-Patients.aspx ]
42. D.C. Xiang Xiang, X.L. Gu, Y.M. Song, W.J. Huang, L.Q. Tang, and Y.H. Yin Evaluation on the efficacy and safety of domestic bivalirudin during percutaneous coronary intervention Chin Med J (Engl) 126 16 2013 3064 3068
43. N.V. Dhespande Deshpande, R. Pratiti, P. Admane, D. Mukherjee, and H.M. Mardikar Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention Indian Heart J 64 5 2012 444 448
44. A. Feldman, K. Suleiman, L. Bushari, E. Rozner, and N.A. Freedberg Bivalirudin Vs Unfractionated Heparin during Percutaneous Coronary Intervention in High Risk Patients for Bleeding. AntiCoagulant Regimen In high risk PAtients for Bleeding - ACRIPAB Trial ESC 2012 [ http://congress365.escardio.org/Interventional-Cardiology-&-Surgery?vgnextkeyword=&Years=C365YEAR2012&ordering=slides%2Cyeardesc%2Ctitle&vgnextsearchresultspageno=2#.VBs9JPl-uSo ]
45. D.J. Moliterno, and TENACITY Steering Committee and Investigators A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial Catheter Cardiovasc Interv 77 7 2011 1001 1009
46. C.M. Gibson Gibson, D.A. Morrow, S.A. Murphy, T.M. Palabrica, L.K. Jennings, and P.H. Stone A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial J Am Coll Cardiol 47 12 2006 2364 2367
47. E.P. Navarese, G. De Luca, F. Castriota, M. Kozinski, P.A. Gurbel, and C.M. Gibson Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis J Thromb Haemost 9 2011 1902 1915
48. G. De Luca, and P. Marino Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment elevation myocardial infarction Thromb Haemost 100 2008 184 195
49. E.P. Navarese, J. Kubica, F. Castriota, C.M. Gibson, G. De Luca, and A. Buffon Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials EuroIntervention 7 2011 985 994
50. C. Capozzolo, F. Piscione, G. De Luca, A. Cioppa, P. Mazzarotto, and D. Leosco Direct coronary stenting: effect on coronary blood flow, immediate and late clinical results Catheter Cardiovasc Interv 53 2001 464 473
51. E. Di Lorenzo, G. De Luca, R. Sauro, A. Varricchio, M. Capasso, and T. Lanzillo The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial JACC Cardiovasc Interv 2 2009 515 523
52. G. De Luca, N. Ernst, A.W. van 't Hof, J.P. Ottervanger, J.C. Hoorntje, and A.T. Gosselink Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction Am Heart J 151 2006 1256 1259
53. G. De Luca, L.A. Małek, P. Maciejewski, W. Wasek, M. Niewada, and B. Kamiński Impact of diabetes on survival in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: insights from the POLISH STEMI registry Atherosclerosis 210 2010 516 520
54. G. De Luca, C.M. Gibson, F. Bellandi, M. Noc, D. Dudek, and U. Zeymer Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors Atherosclerosis 207 2009 181 185
55. G. De Luca, A.C. Maas, H. Suryapranata, J.P. Ottervanger, J.C. Hoorntje, and A.T. Gosselink Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction Am Heart J 150 2005 1248 1254
56. G. De Luca, N. Ernst, H. Suryapranata, J.P. Ottervanger, J.C. Hoorntje, and A.T. Gosselink Relation of interhospital delay and mortality in patients with ST-segment elevation myocardial infarction transferred for primary coronary angioplasty Am J Cardiol 95 2005 1361 1363
57. J.W. Eikelboom, S.R. Mehta, and S.S. Anand Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 114 2006 774 782
58. R. Mehran, S.J. Pocock, and E. Nikolsky A risk score to predict bleeding in patients with acute coronary syndromes J Am Coll Cardiol 55 2010 2556 2566
59. G.W. Stone, T. Clayton, E.N. Deliargyris, J. Prats, R. Mehran, and S.J. Pocock Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) J Am Coll Cardiol 63 2014 15 20
60. K.N. Garratt, H.A. Cohen, and W. Fan Mortality Reductions Linked to Bivalirudin Use in Unselected Angioplasty Patients With and Without Bleeding Complications J Am Coll Cardiol 56 Suppl. 13 2010 B28
61. T. Palmerini, S.J. Brener, R. Mehran, G. Dangas, P. Genereux, and D.D. Riva Leukocyte count is a modulating factor for the mortality benefit of bivalirudin in ST-segment-elevation acute myocardial infarction: the HORIZONS-AMI trial Circ Cardiovasc Interv 6 2013 518 526
62. E.L. Simpson, P. Fitzgerald, P. Evans, P. Tappenden, N. Kalita, and J.P. Reckless Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal Pharmacoeconomics 31 2013 269 275
63. G. Parodi, G. De Luca, G. Moschi, B. Bellandi, R. Valenti, and A. Migliorini Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy J Thromb Thrombolysis 30 2010 446 451
64. G. De Luca, G. Parodi, and D. Antoniucci Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis J Thromb Thrombolysis 30 2010 452 458
65. M.A. Cavender, and M.S. Sabatine Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials Lancet 384 9943 2014 599 606
66. J. MacHaalany, E. Abdelaal, Y. Bataille, G. Plourde, P. Duranleau-Gagnon, and É. Larose Benefit of bivalirudin versus heparin after transradial and transfemoral percutaneous coronary intervention Am J Cardiol 110 2012 1742 1748